Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2021

Open Access 01-12-2021 | Endometriosis | Research

Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)

Authors: Helen Kitchen, Christian Seitz, Andrew Trigg, Natalie Aldhouse, Thomas Willgoss, Heinz Schmitz, Adam Gater, Christoph Gerlinger, Claudia Haberland

Published in: Health and Quality of Life Outcomes | Issue 1/2021

Login to get access

Abstract

Background

The Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS) are patient-reported outcome measures developed to evaluate efficacy in clinical trials and clinical practice. The ESD is a daily electronic diary assessing symptom severity; the EIS is a weekly electronic diary assessing symptom impact. This study explored the importance of symptoms (ESD items) and impacts (EIS domains), perspectives on scoring algorithms, and clinically important difference (CID) thresholds to inform clinical trial score interpretation.

Methods

Endometriosis patients in Germany (n = 8) and the US (n = 17), and expert clinicians (n = 4) in Germany, the US, Spain, and Finland participated in semi-structured qualitative interviews comprising structured tasks. Interview transcripts were analyzed using thematic analysis techniques.

Results

Quality and severity of endometriosis-associated pelvic pain varied considerably among patients; some experienced pelvic pain daily, others during menstrual bleeding (dysmenorrhea) only. Patients and clinicians ranked “worst pelvic pain” as the most meaningful pain concept assessed by the ESD, followed by constant and short-term pelvic pain. Preferences for summarizing daily pain scores over the 28-day menstrual cycle depended on individuals’ experience of pain: patients experiencing pain daily preferred scores summarizing data for all 28 days; patients primarily experiencing pain during selected days, and their treating clinicians preferred scores based on the most severe pain days. Initial CID exploration for the “worst pelvic pain” 0–10 numerical rating scale (0–10 NRS) revealed that, for most patients, a 2- or 3-point reduction was considered meaningful, depending on baseline severity. Patients and clinicians ranked “emotional well-being” and “limitations in physical activities” as the most important EIS domains.

Conclusions

This study informs the use of the ESD and EIS as clinically relevant measures of endometriosis symptoms and their impact. Findings from the ESD highlight the importance of individual-patient assessment of pain experience and identify “worst pelvic pain” as the most meaningful symptom assessed. Aggregating scores over the 28-day menstrual cycle may inform meaningful endpoints for clinical trials. Diverse EIS concepts (e.g. impact on emotional well-being and physical activities) are meaningful to patients and clinicians, emphasizing the importance of evaluating the impact on both to comprehensively assess treatment efficacy and decisions.

Trial registration

Not applicable. Qualitative, non-interventional study; registration not required.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E. Endometriosis ESIGf, Endometrium Guideline Development G: ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20:2698–704.CrossRef Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E. Endometriosis ESIGf, Endometrium Guideline Development G: ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20:2698–704.CrossRef
2.
go back to reference Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier C: consensus on current management of endometriosis. Hum Reprod. 2013;28:1552–68.CrossRef Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier C: consensus on current management of endometriosis. Hum Reprod. 2013;28:1552–68.CrossRef
3.
go back to reference Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009;92:68–74.CrossRef Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009;92:68–74.CrossRef
4.
go back to reference Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6:34–41.CrossRef Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6:34–41.CrossRef
5.
go back to reference Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125:55–62.CrossRef Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125:55–62.CrossRef
6.
go back to reference Leyland N, Casper R, Laberge P, Singh SS. Sogc: endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32:S1-32.CrossRef Leyland N, Casper R, Laberge P, Singh SS. Sogc: endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32:S1-32.CrossRef
7.
go back to reference Klein S, D’Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens S. What is the societal burden of endometriosis-associated symptoms? a prospective Belgian study. Reprod Biomed Online. 2014;28:116–24.CrossRef Klein S, D’Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens S. What is the societal burden of endometriosis-associated symptoms? a prospective Belgian study. Reprod Biomed Online. 2014;28:116–24.CrossRef
8.
go back to reference Dunselman G, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne A, Kiesel L, Nap A. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–12.CrossRef Dunselman G, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne A, Kiesel L, Nap A. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–12.CrossRef
9.
go back to reference Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017;108:125–36.CrossRef Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017;108:125–36.CrossRef
10.
go back to reference Practice Committee of the American Society for Reproductive M. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101:927–35.CrossRef Practice Committee of the American Society for Reproductive M. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101:927–35.CrossRef
11.
go back to reference Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS, Duffy JMN, Farquhar C, Hirsch M, Johnson N, Khan K. Variation in outcome reporting in endometriosis trials: a systematic review. Am J Obstet Gynecol. 2016;214:452–64.CrossRef Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS, Duffy JMN, Farquhar C, Hirsch M, Johnson N, Khan K. Variation in outcome reporting in endometriosis trials: a systematic review. Am J Obstet Gynecol. 2016;214:452–64.CrossRef
12.
go back to reference Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018;110(137–152):e131. Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018;110(137–152):e131.
13.
go back to reference Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M. Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update. 2015;21:136–52.CrossRef Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M. Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update. 2015;21:136–52.CrossRef
14.
go back to reference Gater A, Taylor F, Seitz C, Gerlinger C, Wichmann K, Haberland C. Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary and Endometriosis Impact Scale. J Patient Rep Outcomes. 2020;4:1–17.CrossRef Gater A, Taylor F, Seitz C, Gerlinger C, Wichmann K, Haberland C. Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary and Endometriosis Impact Scale. J Patient Rep Outcomes. 2020;4:1–17.CrossRef
15.
go back to reference van Nooten FE, Cline J, Elash CA, Paty J, Reaney M. Development and content validation of a patient-reported endometriosis pain daily diary. Health Qual Life Outcomes. 2018;16:3.CrossRef van Nooten FE, Cline J, Elash CA, Paty J, Reaney M. Development and content validation of a patient-reported endometriosis pain daily diary. Health Qual Life Outcomes. 2018;16:3.CrossRef
16.
go back to reference Wyrwich KW, O’Brien CF, Soliman AM, Chwalisz K. Development and validation of the endometriosis daily pain impact diary items to assess dysmenorrhea and nonmenstrual pelvic pain. Reprod Sci. 2018a;25:1567–76.CrossRef Wyrwich KW, O’Brien CF, Soliman AM, Chwalisz K. Development and validation of the endometriosis daily pain impact diary items to assess dysmenorrhea and nonmenstrual pelvic pain. Reprod Sci. 2018a;25:1567–76.CrossRef
19.
go back to reference Gater A, Moore A, Coon CD, Chen WH, Wichmann K, Hartisch C, Filonenko A, Seitz C, Gerlinger C. Measuring the symptoms and impacts of endometriosis: psychometric validation of the Endometriosis Symptom Diary and Endometriosis Impact Scale. Value Health. 2015;18:A26.CrossRef Gater A, Moore A, Coon CD, Chen WH, Wichmann K, Hartisch C, Filonenko A, Seitz C, Gerlinger C. Measuring the symptoms and impacts of endometriosis: psychometric validation of the Endometriosis Symptom Diary and Endometriosis Impact Scale. Value Health. 2015;18:A26.CrossRef
20.
go back to reference Gater A, Wichmann K, Seitz C, Gerlinger C, Taylor F, Chen WH, Filonenko A. Assessing the content validity of the endometriosis symptom diary and endometriosis impact scale. Value Health. 2014;17:A198–9.CrossRef Gater A, Wichmann K, Seitz C, Gerlinger C, Taylor F, Chen WH, Filonenko A. Assessing the content validity of the endometriosis symptom diary and endometriosis impact scale. Value Health. 2014;17:A198–9.CrossRef
21.
go back to reference Haberland C, Gater A, Wessiepe D, Schmitz H, Gerlinger C, Seitz C. Psychometric validation of the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS): findings from an interventional study. In: International Society for Quality of Life Research (ISOQOL) 25th annual conference. Dublin, Ireland. 2018. Haberland C, Gater A, Wessiepe D, Schmitz H, Gerlinger C, Seitz C. Psychometric validation of the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS): findings from an interventional study. In: International Society for Quality of Life Research (ISOQOL) 25th annual conference. Dublin, Ireland. 2018.
22.
go back to reference Gater A, Coon CD, Nelsen LM, Girman C. Unique challenges in development, psychometric evaluation, and interpretation of daily and event diaries as endpoints in clinical trials. Ther Innov Regul Sci. 2015;49:813–21.CrossRef Gater A, Coon CD, Nelsen LM, Girman C. Unique challenges in development, psychometric evaluation, and interpretation of daily and event diaries as endpoints in clinical trials. Ther Innov Regul Sci. 2015;49:813–21.CrossRef
24.
go back to reference Coon CD, Cappelleri JC. Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci. 2015;50:22–9.CrossRef Coon CD, Cappelleri JC. Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci. 2015;50:22–9.CrossRef
25.
go back to reference Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, Arbuckle R. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3:16.CrossRef Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, Arbuckle R. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3:16.CrossRef
26.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health. 2011;14:978–88.CrossRef Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health. 2011;14:978–88.CrossRef
29.
go back to reference Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, Hareendran A, Wiklund I, Chong L, von Maltzahn R, et al. Multinational trials—recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report, vol 12. 2009. Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, Hareendran A, Wiklund I, Chong L, von Maltzahn R, et al. Multinational trials—recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report, vol 12. 2009.
30.
go back to reference Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Translation ITFf, cultural A: principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104.CrossRef Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Translation ITFf, cultural A: principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104.CrossRef
31.
go back to reference Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000;16:22–8.CrossRef Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000;16:22–8.CrossRef
32.
go back to reference Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.CrossRef Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.CrossRef
33.
go back to reference Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Thousand Oaks: Sage; 2011. Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Thousand Oaks: Sage; 2011.
34.
go back to reference Germain N, Aballéa S, Andersson FL, Korchagina D, Hawken NA, Toumi M. PIH21—patients’ preferences related to treatments for endometriosis-related pain: results of a discrete choice experiment in the UK. Value Health. 2017;20:A523.CrossRef Germain N, Aballéa S, Andersson FL, Korchagina D, Hawken NA, Toumi M. PIH21—patients’ preferences related to treatments for endometriosis-related pain: results of a discrete choice experiment in the UK. Value Health. 2017;20:A523.CrossRef
35.
go back to reference Aicher B, Peil H, Peil B, Diener HC. Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia. 2012;32:185–97.CrossRef Aicher B, Peil H, Peil B, Diener HC. Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia. 2012;32:185–97.CrossRef
36.
go back to reference Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A. Assessment of pain. Br J Anaesth. 2008;101:17–24.CrossRef Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A. Assessment of pain. Br J Anaesth. 2008;101:17–24.CrossRef
37.
go back to reference Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. Health Qual Life Outcomes. 2010;8:138.CrossRef Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. Health Qual Life Outcomes. 2010;8:138.CrossRef
38.
go back to reference Vannuccini S, Lazzeri L, Orlandini C, Morgante G, Bifulco G, Fagiolini A, Petraglia F. Mental health, pain symptoms and systemic comorbidities in women with endometriosis: a cross-sectional study. J Psychosom Obstet Gynecol. 2017;39:315–20.CrossRef Vannuccini S, Lazzeri L, Orlandini C, Morgante G, Bifulco G, Fagiolini A, Petraglia F. Mental health, pain symptoms and systemic comorbidities in women with endometriosis: a cross-sectional study. J Psychosom Obstet Gynecol. 2017;39:315–20.CrossRef
39.
go back to reference Laganà AS, La Rosa VL, Rapisarda AMC, Valenti G, Sapia F, Chiofalo B, Rossetti D, Ban Frangež H, Vrtačnik Bokal E, Vitale SG. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Women’s Health. 2017;9:323–30.CrossRef Laganà AS, La Rosa VL, Rapisarda AMC, Valenti G, Sapia F, Chiofalo B, Rossetti D, Ban Frangež H, Vrtačnik Bokal E, Vitale SG. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Women’s Health. 2017;9:323–30.CrossRef
40.
go back to reference Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337–45.CrossRef Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337–45.CrossRef
Metadata
Title
Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)
Authors
Helen Kitchen
Christian Seitz
Andrew Trigg
Natalie Aldhouse
Thomas Willgoss
Heinz Schmitz
Adam Gater
Christoph Gerlinger
Claudia Haberland
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Endometriosis
Published in
Health and Quality of Life Outcomes / Issue 1/2021
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-020-01579-7

Other articles of this Issue 1/2021

Health and Quality of Life Outcomes 1/2021 Go to the issue